Doxorubicin in experimental and clinical heart failure

Eur J Cardiothorac Surg. 2006 Oct;30(4):611-6. doi: 10.1016/j.ejcts.2006.06.024. Epub 2006 Aug 8.

Abstract

Doxorubicin-induced heart failure is a rare but serious illness due to the well-known treatment difficulties. Prevention strategies have not demonstrated the expected success and unfortunately, this specific type of heart failure does not respond to the usual medical therapy as other kinds of heart failure. Therefore, surgical procedures may be necessary in some patients. Cardiac transplantation is performed in most cases but it requires the cure of the neoplastic disease. This usually requires a recurrence-free interval of several years which is associated with a high attrition rate in these patients due to their cardiac disease. Therefore, other conservative and surgical treatment concepts were developed during the last years. This review presents the most common procedures and discusses their efficacy as well as their clinical applicability.

Publication types

  • Review

MeSH terms

  • Animals
  • Antibiotics, Antineoplastic / adverse effects*
  • Antibiotics, Antineoplastic / therapeutic use
  • Dogs
  • Doxorubicin / adverse effects*
  • Doxorubicin / therapeutic use
  • Drug Administration Schedule
  • Heart Failure / chemically induced*
  • Heart Failure / prevention & control
  • Heart Failure / surgery
  • Heart Transplantation
  • Humans
  • Models, Animal*
  • Neoplasms / drug therapy
  • Swine

Substances

  • Antibiotics, Antineoplastic
  • Doxorubicin